Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer and BioNTech announced that three doses of their COVID-19 vaccine effectively neutralize the Omicron variant, while two doses show significantly reduced effectiveness. A booster dose increases neutralizing antibody titers by 25-fold against Omicron, similar to the response against the wild-type virus. Despite two doses providing some protection against severe disease, a third dose is recommended for optimal protection. The companies are developing a variant-specific vaccine for Omicron, expected by March 2022, without impacting their production capacity of four billion doses in 2022.
Pfizer Inc. (NYSE: PFE) will hold a live webcast on December 17, 2021, at 8:30 a.m. EST, featuring discussions about the Pfizer-BioNTech COVID-19 vaccine and an oral antiviral treatment candidate. Interested parties can access the webcast via www.pfizer.com/investors. A Q&A session will follow the presentations, with pre-registration advised. The webcast replay will be available for at least 90 days. Pfizer continues to emphasize its commitment to improving healthcare and addressing COVID-19 challenges.
ViiV Healthcare has released survey data for World AIDS Day, revealing significant stigma and misinformation about HIV. Conducted by The Harris Poll among 5,047 adults in the U.S., UK, Australia, and Portugal, the survey found that 88% of respondents perceive ongoing negative attitudes towards individuals living with HIV. It also highlighted that 76% were unaware that effective treatment can prevent HIV transmission. ViiV emphasizes the need for ongoing anti-stigma campaigns, showcasing collaborative efforts like HIV in View.
NiKang Therapeutics has formed a clinical trial collaboration with Pfizer (PFE) to evaluate NKT2152, targeting advanced clear cell renal cell carcinoma (ccRCC). The trial will assess NKT2152 in combination with Pfizer’s palbociclib and sasanlimab for patients unresponsive to prior treatments. NiKang will sponsor the study while Pfizer co-funds it and supplies drugs at no cost. The collaboration aims to leverage complementary pathways for effective therapy. Currently, NKT2152 is in a phase 1/2 trial to determine safety and efficacy.
Pfizer Inc. (NYSE: PFE) invites investors to join a webcast discussion featuring Bob Smith, Vice President of Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference. The event is scheduled for December 1, 2021, at 5:10 p.m. EST. Interested parties can access the webcast on www.pfizer.com/investors. A transcript and replay will be available within 24 hours of the event's conclusion, accessible for at least 90 days on the same site.
The Pfizer-BioNTech COVID-19 vaccine showed 100% efficacy in a longer-term analysis for adolescents aged 12-15, with no serious safety issues reported. This data supports submissions for full regulatory approval in the U.S. and globally. The analysis, part of a pivotal Phase 3 trial, indicated that 0 symptomatic COVID-19 cases occurred in vaccinated participants compared to 30 in the placebo group. The companies plan to submit this data for regulatory review to expand the vaccine's approval.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) have received expanded FDA emergency use authorization for the COVID-19 booster dose for individuals 18 and older. The booster, to be administered at least six months post-primary series, aims to sustain high protection against COVID-19 variants, including Delta. Clinical trials indicated a vaccine efficacy of 95% for booster recipients. The companies expect no impact on existing supply agreements. The FDA's decision is crucial as the pandemic continues to evolve.
Pfizer Inc. (NYSE: PFE) announced that the European Commission has approved XELJANZ® (tofacitinib) at 5 mg twice daily for adults with active ankylosing spondylitis (AS) who do not respond adequately to conventional therapies. XELJANZ is the first oral Janus kinase (JAK) inhibitor approved for five indications in the EU. The approval is based on a Phase 3 study involving 269 patients, which demonstrated significant efficacy over placebo (ASAS20: 56.4% vs. 29.4%, p0.0001). The approval aims to fulfill an unmet medical need for over one million AS patients in the EU.
Cardiff Oncology (Nasdaq: CRDF) announced a $15 million equity investment from Pfizer (NYSE: PFE) to support its clinical programs for KRAS-mutated cancers, including colorectal and pancreatic cancer. Pfizer acquired 2.4 million shares at $6.22 each as part of its Breakthrough Growth Initiative. This collaboration aims to enhance Cardiff's efforts in developing onvansertib, a PLK1 inhibitor, alongside leveraging data from their clinical trials. Pfizer's VP, Adam Schayowitz, is set to join Cardiff's Scientific Advisory Board to further assist in innovative cancer therapies.
Pfizer has announced a supply agreement with the U.S. government for PAXLOVID™ (PF-07321332; ritonavir), pending FDA authorization. The deal includes 10 million treatment courses for $5.29 billion, reflecting a commitment to ensuring equitable access across various income levels. PAXLOVID, a novel oral antiviral designed to combat SARS-CoV-2, showed an 89% reduction in COVID-19-related hospitalization or death in clinical trials. Pfizer is pursuing regulatory approvals globally while investing $1 billion to enhance manufacturing and distribution.